First-in-man Trial Evaluating the Safety and Efficacy of the NOVA Intracranial Stent (NOVA Trial)

Inclusion Criteria: 1. 18 to 75 years of age; 2. Primary or recurrent symptomatic intracranial arteriostenosis through the internal medicine treatment (i.e. stroke or transient ischemic attack within 90 days during the treatment with at least one anti-thrombotic drugs and vascular risk factor intervention e.g. hypertensors for hypertension and hypolipidemics for hyperlipidemia); 3. No transient ischemic attack (TIA) or ischemic stroke occurred within 2 weeks prior to stenting procedure; 4. ≥70% stenosis of intracranial responsible vessel under the DSA angiography (as judged through the WASID method); 5. Poor blood circulation in the side branch of responsible vessel area under the angiography within one week prior to stenting procedure: Score of blood circulation in the side branch under the DSA \<3 or blood flow rate peak ≥200cm/s at the systolic phase under the transcranial doppler ultrasonic examination (TCD); or no apparent side branch compensation in the responsible vessel area under CTA or score of blood circulation in the side branch under the CTA \<2; 6. The target lesion reference diameter must be visually estimated to be ≥2.0 mm in diameter, and lesion length must be \<15 mm; no lesion observed in the distal vessel; 7. Atherosclerosis lesions; 8. mRS \< 3; 9. Written informed consent. Exclusion Criteria: 1. \>70% intracranial large-vessel stenosis beyond the responsible vessel; 2. \>70% stenosis observed at the intracranial large-vessel distal to the responsible vessel or \>70% stenosis observed at the intracranial/extracranial large-vessel proximal to the responsible vessel; 3. Acute ischemic stroke within 3 weeks; 4. Obstruction of perforating branch artery under the skull MRI; 5. Intracranial hemorrhage in the angiopathic area within 6 weeks; 6. Patient was treated by thrombolytic therapy within 24 hours; 7. Patients underwent surgery within 30 days or plan for surgery within 3 months post-stenting procedure; 8. Severe calcified lesions; 9. Patients have been treated by intracranial/extracranial stenting procedures prior to this study; 10. Nonatherosclerosis lesions; 11. Patients with potential sources for cardiac embolism; 12. Concomitant intracranial tumor, aneurysm or intracranial arteriovenous malformation; 13. Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study, sirolimus, poly(lactic-co-glycolic acid) polymers, or poly(n-butyl methacrylate); 14. Hemoglobin \<100g/L, platelet count \<100,000 cells/mm3, International normalized ratio (INR) \>1.5 (irreversible) or uncorrectable hemorrhagic factors; 15. Serious neural dysfunction due to the responsible angiopathy as the sequel of cerebral infarction (mRS≥3); 16. Known liver or renal insufficiency (ALT\> 3x upper limit or AST \> 3x upper limit, creatinine \> 1.5x upper limit); 17. Life expectancy \< 2 years; 18. Pregnant/lactating female patients; 19. Patients with cognitive impairment or mental diseases; 20. The patient participated in another investigational device or drug study within 3 months; 21. Inapplicable for intravascular stenting treatment as per investigators judgment.